These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38443119)

  • 1. Novel Clinical Applications of Topical Ruxolitinib: A Case Series.
    Zundell MP; Al-Dehneem R; Song T; Yousif J; Gottlieb AB
    J Drugs Dermatol; 2024 Mar; 23(3):188-190. PubMed ID: 38443119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
    Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
    Front Immunol; 2020; 11():620098. PubMed ID: 33658996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo.
    Grossmann MC; Haidari W; Feldman SR
    J Drugs Dermatol; 2023 Jul; 22(7):664-667. PubMed ID: 37410047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
    Kang C
    Drugs; 2024 May; 84(5):579-586. PubMed ID: 38625661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo.
    Agner ML; Parraga SP; Arkhipenko ZM; Pichardo RO; McMichael AJ; Feldman SR
    Expert Rev Clin Immunol; 2024 Jul; 20(7):695-702. PubMed ID: 38879876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.
    Gong X; Chen X; Kuligowski ME; Liu X; Liu X; Cimino E; McGee R; Yeleswaram S
    Am J Clin Dermatol; 2021 Jul; 22(4):555-566. PubMed ID: 33982267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata.
    Tembunde Y; Kindred C
    J Drugs Dermatol; 2024 May; 23(5):378-379. PubMed ID: 38709705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year.
    Hu W; Thornton M; Livingston RA
    Am J Clin Dermatol; 2024 Mar; 25(2):327-332. PubMed ID: 38243107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
    Kołodrubiec J; Kozłowska M; Irga-Jaworska N; Sędek Ł; Pastorczak A; Trelińska J; Młynarski W
    Leuk Res; 2022 Oct; 121():106925. PubMed ID: 35939887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
    Goker Bagca B; Biray Avci C
    Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of therapeutic trials of topical ruxolitinib cream for the treatment of vitiligo: therapeutic efficacy, safety, and implications for therapeutic practice.
    Hussein AFA; Shams AS; Hosny N; Elrosasy A; Kobtan M; Shafik YA; Alnatsheh ZR; Zeid MA; Qarma M; Ibrahim YK; Al-Sultany HA
    Arch Dermatol Res; 2024 Aug; 316(8):518. PubMed ID: 39134884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
    Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review.
    Dogra S; Sharma A; Mehta H; Sarkar R
    Clin Exp Dermatol; 2023 Sep; 48(10):1102-1112. PubMed ID: 37235767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Off-label Studies on the Use of Ruxolitinib in Dermatology.
    Tegtmeyer K; Ravi M; Zhao J; Maloney NJ; Lio PA
    Dermatitis; 2021 May-Jun 01; 32(3):164-172. PubMed ID: 33443378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report.
    Powers CM; Verma H; Orloff J; Piontkowski AJ; Tiersten A; Lamb A; Gulati N
    J Dermatolog Treat; 2024 Dec; 35(1):2336118. PubMed ID: 38565207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of Topical Ruxolitinib in Dermatology: A Review.
    Kashetsky N; Turchin I
    Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of Safety, Efficacy, and Patient Counseling for Ruxolitinib in Treating Atopic Dermatitis.
    Mancuso-Stewart E; Rodger J; Zirwas M
    Skinmed; 2023; 21(1):40-43. PubMed ID: 36987827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
    Huang IH; Chung WH; Wu PC; Chen CB
    Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of JAK/STAT inhibitors on human monocyte-derived-macrophages stimulated by cigarette smoke extract and lipopolysaccharide.
    Verres Y; da Silva CO; Aljebawi B; Bodin A; Barreto E; Lagente V; Victoni T
    Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1187-1196. PubMed ID: 35876719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
    Garcia-Melendo C; Cubiró X; Puig L
    Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.